| Symbol | AGEN |
|---|---|
| Name | AGENUS INC |
| Sector | HEALTH CARE |
| Region | UNDEFINED |
| Industry | Biological Products, (No Diagnostic Substances) |
| Address | 3 FORBES ROAD, LEXINGTON, MA 02421 |
| Telephone | 781-674-4410 |
| Fax | — |
| — | |
| Website | https://www.agenusbio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The companys portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharpe & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs. Some of its products include Prophage, AutoSynVax, QS-21 Stimulon, and others. Additional info from NASDAQ: |
2026-04-22 00:56
Agenus nomeia a BAP Pharma como parceira global exclusiva para os programas de acesso BOT+BAL
Read more
2026-04-22 00:56
Agenus nomina BAP Pharma partner esclusivo globale per i programmi di accesso a BOT+BAL
Read more
2026-04-22 00:55
Agenus désigne BAP Pharma comme partenaire mondial exclusif pour les programmes d’accès à la combinaison BOT+BAL
Read more
2026-04-22 00:55
Agenus ernennt BAP Pharma zum exklusiven globalen Partner für die BOT+BAL-Zugangsprogramme
Read more
2026-04-22 00:55
Agenus benoemt BAP Pharma tot exclusieve wereldwijde partner voor de BOT+BAL-toegangsprogramma’s
Read more
2026-04-21 20:15
ARMEN GARO H 🟢 acquired 3.4K shares of AGENUS INC (AGEN) at $4.79 Transaction Date: Apr 17, 2026 | Filing ID: 166818
Read more
2026-04-21 14:00
Agenus Inc. - Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05572970 | Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelim… | — | Cancer | Available | — | — | ClinicalTrials.gov |
| NCT06751524 | Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Ba… | — | Colorectal Cancer (CRC) | Available | — | — | ClinicalTrials.gov |
| NCT07152821 | Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refracto… | Phase3 | Colorectal Cancer | Recruiting | 2026-03-31 | 2029-06-30 | ClinicalTrials.gov |
| NCT07128355 | Botensilimab, Balstilimab, and SBRT in Colorectal Cancer | Early_Phase1 | Non-MSI-H or pMMR Colorectal Cancer With Liver Metastasis | Not_Yet_Recruiting | 2026-02-01 | 2027-09-01 | ClinicalTrials.gov |
| NCT06346197 | Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Eso… | Phase3 | Gastric Cancer | Recruiting | 2025-12-08 | 2028-05-15 | ClinicalTrials.gov |
| NCT07227636 | A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After… | Phase2 | Colorectal Cancer | Recruiting | 2025-11-07 | 2030-11-01 | ClinicalTrials.gov |
| NCT06411691 | KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients W… | Phase1 | Colorectal Cancer | Recruiting | 2025-06-24 | 2029-07-01 | ClinicalTrials.gov |
| NCT06843551 | The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Imm… | Phase2 | Metastatic Pancreatic Ductal Adenocarcinoma | Recruiting | 2025-06-18 | 2030-08-01 | ClinicalTrials.gov |
| NCT06782932 | Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti… | Phase1 | Pancreatic Cancer | Recruiting | 2025-05-27 | 2028-12-01 | ClinicalTrials.gov |
| NCT06843434 | A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma | Phase2 | Microsatellite Stable Rectal Carcinoma | Recruiting | 2025-02-20 | 2028-02-20 | ClinicalTrials.gov |
| NCT06076837 | The Seven Trial: Exploiting the Unfolded Protein Response | Phase1 | Pancreatic Cancer Metastatic | Active_Not_Recruiting | 2025-01-09 | 2026-12-01 | ClinicalTrials.gov |
| NCT06782555 | A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab | Phase1 | Metastatic Prostate Cancer | Recruiting | 2025-01-08 | 2028-01-01 | ClinicalTrials.gov |
| NCT06268015 | Botensilimab and Balstilimab Optimization in Colorectal Cancer | Phase2 | Colorectal Cancer | Active_Not_Recruiting | 2024-11-18 | 2028-07-01 | ClinicalTrials.gov |
| NCT06322108 | Assessment of the Safety and Efficacy of Balstilimab in Combination With Botens… | Phase2 | Non-small Cell Lung Cancer | Recruiting | 2024-06-13 | 2030-04-01 | ClinicalTrials.gov |
| NCT06300463 | Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metasta… | Phase2 | Colorectal Cancer Metastatic | Recruiting | 2024-03-26 | 2027-12-01 | ClinicalTrials.gov |
| NCT05864534 | Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma | Phase2 | Newly Diagnosed Glioblastoma | Recruiting | 2024-01-31 | 2026-08-01 | ClinicalTrials.gov |
| NCT06279130 | Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel I… | Phase2 | Resectable MMR-deficient Solid Tumors | Recruiting | 2024-01-29 | 2034-01-29 | ClinicalTrials.gov |
| NCT06095674 | ImmunoTHerapy Adjacent to Cervical CAncer (ITHACA) Study | Phase1 | Cervical Cancer | Not_Yet_Recruiting | 2024-01-01 | 2026-01-01 | ClinicalTrials.gov |
| NCT05561491 | A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanc… | Phase2 | Melanoma | Withdrawn | 2024-01-01 | 2027-06-01 | ClinicalTrials.gov |
| NCT05363709 | BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients | Phase2 | HPV | Active_Not_Recruiting | 2023-10-18 | 2028-02-15 | ClinicalTrials.gov |
| NCT05318469 | Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Me… | Phase1 | Anatomic Stage IV Breast Cancer AJCC v8 | Recruiting | 2023-10-13 | 2026-10-01 | ClinicalTrials.gov |
| NCT05928806 | Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial | Phase2 | Advanced Renal Cell Carcinoma | Suspended | 2023-09-25 | 2027-11-10 | ClinicalTrials.gov |
| NCT05891821 | Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relap… | Phase2 | Lymphoma | Recruiting | 2023-09-01 | 2029-09-01 | ClinicalTrials.gov |
| NCT05630183 | A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer | Phase2 | Metastatic Pancreatic Ductal Adenocarcinoma | Active_Not_Recruiting | 2023-03-27 | 2025-12-05 | ClinicalTrials.gov |
| NCT05571293 | Combination Immunotherapy in Colorectal Cancer | Phase2 | Colorectal Neoplasms | Suspended | 2023-03-17 | 2026-06-01 | ClinicalTrials.gov |
| NCT05529316 | A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma | Phase2 | Advanced Melanoma | Active_Not_Recruiting | 2022-12-12 | 2028-02-01 | ClinicalTrials.gov |
| NCT05608044 | A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer | Phase2 | Metastatic Colorectal Cancer | Active_Not_Recruiting | 2022-11-30 | 2029-09-01 | ClinicalTrials.gov |
| NCT05377528 | Study of AGEN1571 in Participants With Advanced Solid Tumors | Phase1 | Advanced Solid Tumor | Completed | 2022-07-19 | 2024-12-23 | ClinicalTrials.gov |
| NCT05205330 | Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refracto… | Phase1 | Refractory Metastatic Colorectal Cancer | Active_Not_Recruiting | 2021-11-23 | 2027-06-01 | ClinicalTrials.gov |
| NCT05033132 | A Phase II Study of Balstilimab Independently or in Combination With Zalifrelim… | Phase2 | Cervical Cancer | Withdrawn | 2021-10-01 | 2024-12-30 | ClinicalTrials.gov |
| NCT04827953 | Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standar… | Phase1 | Pancreatic Ductal Adenocarcinoma | Active_Not_Recruiting | 2021-09-01 | 2025-04-01 | ClinicalTrials.gov |
| NCT04943627 | Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent … | Phase3 | Advanced Cancer | Withdrawn | 2021-08-02 | 2021-10-22 | ClinicalTrials.gov |
| NCT04607200 | AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma | Phase2 | Angiosarcoma | Withdrawn | 2021-02-01 | 2021-09-13 | ClinicalTrials.gov |
| NCT04028063 | Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas | Phase2 | Metastatic Soft Tissue Sarcoma | Recruiting | 2020-01-28 | 2027-12-31 | ClinicalTrials.gov |
| NCT04156100 | A Study in Subjects With Advanced Solid Tumors | Phase1 | Advanced Solid Tumor | Terminated | 2019-12-10 | 2021-09-29 | ClinicalTrials.gov |
| NCT04121676 | Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer | Phase1 | Advanced Cancer | Completed | 2019-09-26 | 2024-11-30 | ClinicalTrials.gov |
| NCT03894215 | RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-… | Phase2 | Cervical Cancer | Terminated | 2019-06-01 | 2025-03-26 | ClinicalTrials.gov |
| NCT03673020 | Phase 1a Study to Evaluate Immunogenicity of ASV® | Phase1 | Solid Tumor, Adult | Completed | 2019-05-16 | 2021-02-03 | ClinicalTrials.gov |
| NCT03860272 | Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer | Phase1 | Advanced Cancer | Active_Not_Recruiting | 2019-03-20 | 2027-12-01 | ClinicalTrials.gov |
| NCT03495882 | Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into S… | Phase1 | Cervical Cancer | Completed | 2017-12-18 | 2022-07-15 | ClinicalTrials.gov |
| NCT03411473 | Study of AGEN1884 With Pembrolizumab in 1L NSCLC | Phase2 | NSCLC Stage IV | Terminated | 2017-10-04 | 2019-03-01 | ClinicalTrials.gov |
| NCT03104699 | A Study of AGEN2034 in Advanced Tumors and Cervical Cancer | Phase1 | Advanced Cancer | Completed | 2017-04-11 | 2022-06-15 | ClinicalTrials.gov |
| NCT02992977 | Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced … | Phase1 | Advanced Cancer | Terminated | 2017-01-01 | 2019-12-01 | ClinicalTrials.gov |
| NCT02694822 | AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advance… | Phase1 | Advanced Solid Cancers | Completed | 2016-04-01 | 2022-03-31 | ClinicalTrials.gov |
| NCT02452281 | Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipili… | Phase1 | Melanoma | Withdrawn | 2015-12-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT01814813 | Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients … | Phase2 | Recurrent Glioblastoma | Terminated | 2013-06-19 | 2023-05-22 | ClinicalTrials.gov |
| NCT01687595 | Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants Wit… | Phase2 | Herpes Simplex Type 2 | Completed | 2012-10-29 | 2015-01-01 | ClinicalTrials.gov |
| NCT01147536 | Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Par… | Phase2 | Renal Cell Carcinoma | Terminated | 2010-01-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT00905060 | HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM | Phase2 | Brain and Central Nervous System Tumors | Completed | 2009-06-29 | 2014-06-03 | ClinicalTrials.gov |
| NCT00231049 | Trial Evaluating Safety, Tolerability and Immune Response of AG-707 | Phase1 | Genital Herpes | Completed | 2006-03-01 | — | ClinicalTrials.gov |
| NCT00316511 | Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-C… | Phase1 | Malignancies | Completed | 2006-03-01 | — | ClinicalTrials.gov |
| NCT00293423 | GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recur… | Phase1 | Brain and Central Nervous System Tumors | Completed | 2005-11-18 | 2013-01-12 | ClinicalTrials.gov |
| NCT00126178 | Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-meta… | Phase3 | Kidney Cancer | Terminated | 2005-05-01 | 2006-03-01 | ClinicalTrials.gov |
| NCT00098085 | Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With N… | Phase2 | Non-Small-Cell Lung Carcinoma | Completed | 2003-09-01 | — | ClinicalTrials.gov |
| NCT00058747 | AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleeve… | Phase2 | Leukemia, Myeloid, Chronic | Terminated | 2003-03-01 | 2006-04-01 | ClinicalTrials.gov |
| NCT00082459 | Trial to Compare the Routes of Administration of an Investigational, Personaliz… | Phase2 | Renal Cell Carcinoma | Terminated | 2002-07-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00039000 | Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Sta… | Phase3 | Malignant Melanoma | Completed | 2002-03-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00033904 | Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer | Phase3 | Renal Cell Carcinoma | Completed | 2000-06-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00081809 | A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent L… | Phase2 | Lymphoma, Follicular | Completed | 2000-03-01 | 2005-06-01 | ClinicalTrials.gov |
Total clinical trials: 59
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Botensilimab | Other | Phase PHASE3 | Colorectal Cancer | RECRUITING | NCT07152821 |
| Balstilimab | Other | Phase PHASE3 | Colorectal Cancer | RECRUITING | NCT07152821 |
| Best Supportive Care | Other | Phase PHASE3 | Colorectal Cancer | RECRUITING | NCT07152821 |
| Botensilimab | Other | Phase PHASE3 | Colorectal Cancer | RECRUITING | NCT07152821 |
| Balstilimab | Other | Phase PHASE3 | Colorectal Cancer | RECRUITING | NCT07152821 |
| Best Supportive Care | Other | Phase PHASE3 | Colorectal Cancer | RECRUITING | NCT07152821 |
| Botensilimab | Other | Phase PHASE3 | Colorectal Cancer | RECRUITING | NCT07152821 |
| Balstilimab | Other | Phase PHASE3 | Colorectal Cancer | RECRUITING | NCT07152821 |
| Best Supportive Care | Other | Phase PHASE3 | Colorectal Cancer | RECRUITING | NCT07152821 |
| Botensilimab | Other | Phase PHASE3 | Colorectal Cancer | RECRUITING | NCT07152821 |
| Balstilimab | Other | Phase PHASE3 | Colorectal Cancer | RECRUITING | NCT07152821 |
| Best Supportive Care | Other | Phase PHASE3 | Colorectal Cancer | RECRUITING | NCT07152821 |
| Botensilimab | Other | Phase PHASE3 | Colorectal Cancer | RECRUITING | NCT07152821 |
| Balstilimab | Other | Phase PHASE3 | Colorectal Cancer | RECRUITING | NCT07152821 |
| Best Supportive Care | Other | Phase PHASE3 | Colorectal Cancer | RECRUITING | NCT07152821 |
| Nivolumab | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| XELOX | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Folfox Protocol | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Botensilimab | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Balstilimab | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Botensilimab | Other | Phase PHASE3 | Colorectal Cancer | RECRUITING | NCT07152821 |
| Balstilimab | Other | Phase PHASE3 | Colorectal Cancer | RECRUITING | NCT07152821 |
| Best Supportive Care | Other | Phase PHASE3 | Colorectal Cancer | RECRUITING | NCT07152821 |
| Nivolumab | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| XELOX | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Folfox Protocol | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Botensilimab | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Balstilimab | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Botensilimab | Other | Phase PHASE3 | Colorectal Cancer | RECRUITING | NCT07152821 |
| Balstilimab | Other | Phase PHASE3 | Colorectal Cancer | RECRUITING | NCT07152821 |
| Best Supportive Care | Other | Phase PHASE3 | Colorectal Cancer | RECRUITING | NCT07152821 |
| Nivolumab | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| XELOX | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Folfox Protocol | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Botensilimab | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Balstilimab | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Nivolumab | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| XELOX | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Folfox Protocol | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Botensilimab | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Balstilimab | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Nivolumab | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| XELOX | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Folfox Protocol | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Botensilimab | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Balstilimab | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Nivolumab | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| XELOX | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Folfox Protocol | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Botensilimab | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Balstilimab | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Nivolumab | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| XELOX | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Folfox Protocol | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Botensilimab | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Balstilimab | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Nivolumab | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| XELOX | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Folfox Protocol | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Botensilimab | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Balstilimab | Other | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Botensilimab | Other | Phase PHASE3 | Colorectal Cancer | RECRUITING | NCT07152821 |
| Balstilimab | Other | Phase PHASE3 | Colorectal Cancer | RECRUITING | NCT07152821 |
| Best Supportive Care | Other | Phase PHASE3 | Colorectal Cancer | RECRUITING | NCT07152821 |
| Botensilimab | Other | Phase PHASE3 | Colorectal Cancer | RECRUITING | NCT07152821 |
| Balstilimab | Other | Phase PHASE3 | Colorectal Cancer | RECRUITING | NCT07152821 |
| Best Supportive Care | Other | Phase PHASE3 | Colorectal Cancer | RECRUITING | NCT07152821 |
| Botensilimab | Other | Phase PHASE3 | Colorectal Cancer | RECRUITING | NCT07152821 |
| Balstilimab | Other | Phase PHASE3 | Colorectal Cancer | RECRUITING | NCT07152821 |
| Best Supportive Care | Other | Phase PHASE3 | Colorectal Cancer | RECRUITING | NCT07152821 |
| Botensilimab | Other | Phase PHASE3 | Colorectal Cancer | RECRUITING | NCT07152821 |
| Balstilimab | Other | Phase PHASE3 | Colorectal Cancer | RECRUITING | NCT07152821 |
| Best Supportive Care | Other | Phase PHASE3 | Colorectal Cancer | RECRUITING | NCT07152821 |
| Best Supportive Care | OTHER | Phase PHASE3 | Colorectal Cancer | RECRUITING | NCT07152821 |
| Stereotactic Body Radiation Therapy (SBRT) | RADIATION | Phase EARLY_PHASE1 | Non-MSI-H or pMMR Colorectal Cancer With Liver Metastasis | NOT_YET_RECRUITING | NCT07128355 |
| Stereotactic Body Radiation Therapy | RADIATION | Phase PHASE2 | Metastatic Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT06843551 |
| mKRASvax | DRUG | Phase PHASE1 | Pancreatic Cancer | RECRUITING | NCT06782932 |
| AGEN2373 (RP2D) | DRUG | Phase PHASE1 | Pancreatic Cancer | RECRUITING | NCT06782932 |
| GVAX | DRUG | Phase PHASE1 | Pancreatic Cancer | RECRUITING | NCT06782932 |
| Cyclophosphamide | DRUG | Phase PHASE1 | Pancreatic Cancer | RECRUITING | NCT06782932 |
| Evofosfamide | DRUG | Phase PHASE1 | Metastatic Prostate Cancer | RECRUITING | NCT06782555 |
| Balstililmab | DRUG | Preclinical | Colorectal Cancer (CRC) | AVAILABLE | NCT06751524 |
| KRAS Vaccine with Poly-ICLC adjuvant | DRUG | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT06411691 |
| XELOX | DRUG | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Folfox Protocol | DRUG | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Botensilimab + Balstilimab | DRUG | Phase PHASE2 | Non-small Cell Lung Cancer | RECRUITING | NCT06322108 |
| Radiation | RADIATION | Phase PHASE2 | Colorectal Cancer Metastatic | RECRUITING | NCT06300463 |
| FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel) | DRUG | Phase PHASE2 | Resectable MMR-deficient Solid Tumors | RECRUITING | NCT06279130 |
| balstilimab | DRUG | Phase PHASE2 | Resectable MMR-deficient Solid Tumors | RECRUITING | NCT06279130 |
| botensilimab | DRUG | Phase PHASE2 | Resectable MMR-deficient Solid Tumors | RECRUITING | NCT06279130 |
| Panitumumab | DRUG | Phase PHASE2 | Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT06268015 |
| Bevacizumab | DRUG | Phase PHASE2 | Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT06268015 |
| Fluorouracil | DRUG | Phase PHASE2 | Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT06268015 |
| Leucovorin | DRUG | Phase PHASE2 | Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT06268015 |
| Oxaliplatin | DRUG | Phase PHASE2 | Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT06268015 |
| Anti-PD-1 antibody balstilimab | DRUG | Phase PHASE1 | Cervical Cancer | NOT_YET_RECRUITING | NCT06095674 |
| Cisplatin | DRUG | Phase PHASE1 | Pancreatic Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT06076837 |
| Celecoxib | DRUG | Phase PHASE1 | Pancreatic Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT06076837 |
| Chloroquine Phosphate | DRUG | Phase PHASE1 | Pancreatic Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT06076837 |
| Nivolumab | DRUG | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Ipilimumab | DRUG | Phase PHASE2 | Advanced Renal Cell Carcinoma | SUSPENDED | NCT05928806 |
| Sonocloud-9 (SC-9) | DEVICE | Phase PHASE2 | Newly Diagnosed Glioblastoma | RECRUITING | NCT05864534 |
| Liposomal Doxorubicin | DRUG | Phase PHASE2 | Newly Diagnosed Glioblastoma | RECRUITING | NCT05864534 |
| AGEN1423 | DRUG | Phase PHASE2 | Advanced Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05632328 |
| Nab-paclitaxel | DRUG | Phase PHASE2 | Advanced Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05632328 |
| Standard of Care | DRUG | Phase PHASE2 | Metastatic Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT05608044 |
| ONCOS-102 | BIOLOGICAL | Phase PHASE2 | Melanoma | WITHDRAWN | NCT05561491 |
| AGEN1571 | DRUG | Phase PHASE1 | Advanced Solid Tumor | COMPLETED | NCT05377528 |
| Pembrolizumab | DRUG | Phase PHASE1 | Anatomic Stage IV Breast Cancer AJCC v8 | RECRUITING | NCT05318469 |
| Balstilmab | DRUG | Phase PHASE1 | Anatomic Stage IV Breast Cancer AJCC v8 | RECRUITING | NCT05318469 |
| Ivermectin | DRUG | Phase PHASE1 | Anatomic Stage IV Breast Cancer AJCC v8 | RECRUITING | NCT05318469 |
| CR6086 | DRUG | Phase PHASE1 | Refractory Metastatic Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT05205330 |
| Balstilimab + Zalifrelimab | DRUG | Phase PHASE2 | Cervical Cancer | WITHDRAWN | NCT05033132 |
| a PD-1 inhibitor | DRUG | Phase PHASE1 | Advanced Cancer | COMPLETED | NCT05025085 |
| AGEN1777 | DRUG | Phase PHASE1 | Advanced Cancer | COMPLETED | NCT05025085 |
| Pemetrexed | DRUG | Phase PHASE3 | Advanced Cancer | WITHDRAWN | NCT04943627 |
| Irinotecan | DRUG | Phase PHASE3 | Advanced Cancer | WITHDRAWN | NCT04943627 |
| Vinorelbine | DRUG | Phase PHASE3 | Advanced Cancer | WITHDRAWN | NCT04943627 |
| Topotecan | DRUG | Phase PHASE3 | Advanced Cancer | WITHDRAWN | NCT04943627 |
| Balstilimab (BAL) | DRUG | Phase PHASE3 | Advanced Cancer | WITHDRAWN | NCT04943627 |
| NLM-001 | DRUG | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT04827953 |
| Nab paclitaxel | DRUG | Phase PHASE1 | Pancreatic Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT06076837 |
| Gemcitabine | DRUG | Phase PHASE2 | Advanced Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05632328 |
| AGEN1223 and balstilimab | DRUG | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT04156100 |
| AGEN1223 | DRUG | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT04156100 |
| AGEN2373 | DRUG | Phase PHASE1 | Pancreatic Cancer | RECRUITING | NCT06782932 |
| Doxorubicin | DRUG | Phase PHASE2 | Metastatic Soft Tissue Sarcoma | RECRUITING | NCT04028063 |
| AGEN1884 | DRUG | Phase PHASE2 | Angiosarcoma | WITHDRAWN | NCT04607200 |
| Balstilimab | DRUG | Phase PHASE3 | Gastric Cancer | RECRUITING | NCT06346197 |
| Botensilimab | DRUG | Phase PHASE2 | Advanced Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05632328 |
| ASV® AGEN2017 + QS-21 Stimulon® adjuvant | BIOLOGICAL | Phase PHASE1 | Solid Tumor, Adult | COMPLETED | NCT03673020 |
| AGEN1884 + AGEN2034 | DRUG | Phase PHASE1 | Cervical Cancer | COMPLETED | NCT03495882 |
| AGEN1884 in combination with pembrolizumab | BIOLOGICAL | Phase PHASE2 | NSCLC Stage IV | TERMINATED | NCT03411473 |
| AGEN2034 | BIOLOGICAL | Phase PHASE1 | Refractory Metastatic Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT05205330 |
| AutoSynVax™ vaccine | BIOLOGICAL | Phase PHASE1 | Advanced Cancer | TERMINATED | NCT02992977 |
| Zalifrelimab | DRUG | Phase PHASE1 | Metastatic Prostate Cancer | RECRUITING | NCT06782555 |
| ipilimumab | DRUG | Phase PHASE1 | Melanoma | WITHDRAWN | NCT02452281 |
| bevacizumab | DRUG | Phase PHASE2 | Recurrent Glioblastoma | TERMINATED | NCT01814813 |
| Placebo | OTHER | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07227636 |
| HerpV and QS-21 | DRUG | Phase PHASE2 | Herpes Simplex Type 2 | COMPLETED | NCT01687595 |
| Temozolomide | DRUG | Phase PHASE2 | Brain and Central Nervous System Tumors | COMPLETED | NCT00905060 |
| Aroplatin | DRUG | Phase PHASE1 | Malignancies | COMPLETED | NCT00316511 |
| Standard Surgical Resection | PROCEDURE | Phase PHASE2 | Brain and Central Nervous System Tumors | COMPLETED | NCT00905060 |
| AG-707 | DRUG | Phase PHASE1 | Genital Herpes | COMPLETED | NCT00231049 |
| HSPPC-96 | DRUG | Phase PHASE1 | Melanoma | WITHDRAWN | NCT02452281 |
| Autologous HSP-70 Protein-Peptide Complex (AG-858) Plus Gleevec™. | DRUG | Phase PHASE2 | Leukemia, Myeloid, Chronic | TERMINATED | NCT00058747 |
| HSPPC-96 or Oncophage | DRUG | Phase PHASE3 | Malignant Melanoma | COMPLETED | NCT00039000 |
| autologous human tumor-derived HSPPC-96 | BIOLOGICAL | Phase PHASE2 | Renal Cell Carcinoma | TERMINATED | NCT00082459 |
Total products: 148